Biotron appoints Penthrox veteran to steer SedRx and antiviral programs

Biotron appoints experienced life sciences executive

Biotron Limited (ASX:BIT) has chosen an executive with experience taking medical products through clinical development, regulation and international commercialisation to lead its next phase. Glenn Gilbert will become chief executive officer and executive director on 18 January 2027, succeeding the current leadership as the company works across its SedRx anaesthetic and antiviral programs.

Gilbert has more than 20 years’ experience spanning pharmaceuticals, medical devices and in-vitro diagnostics. He is currently chief executive of unlisted medical device developer Inspiring Holdings, and previously led ASX-listed Rhythm Biosciences (ASX:RHY). Before that, he held senior roles at Medical Developments International (ASX:MVP), where he was involved in the clinical development and international commercialisation of Penthrox, as well as roles with CSL/Seqirus.

SedRx and antiviral programs form the immediate brief

Biotron’s appointment comes as its SedRx program moves towards a more demanding development pathway. Earlier company updates said European Medicines Agency feedback ruled out a Hybrid Marketing Authorisation route and pointed the company towards pivotal clinical trials, a shift captured in the EMA SedRx feedback. The filing does not provide a new timetable, trial design or funding estimate for that work.

Gilbert will also inherit Biotron’s antiviral portfolio, including BIT-HBV001. Earlier reporting said the candidate showed activity against Hepatitis Delta Virus, while the new announcement provides no additional efficacy data or development milestone. The incoming CEO said his near-term priorities would be to assess work completed to date, establish a development plan, set capital allocation priorities and focus the company on clinical, regulatory and commercial milestones.

Performance-linked package carries dilution and cash questions

Gilbert’s annual salary is set at $250,000 plus statutory superannuation. His incentive package allows for up to 100 million unlisted options with an exercise price of $0.0041, subject to milestone conditions under Biotron’s employee incentive scheme, alongside up to $230,000 in cash bonus payments tied to milestones.

The announcement does not disclose those milestone conditions, so shareholders cannot yet assess how the incentives map to clinical, regulatory or commercial outcomes. If the options are issued and later exercised, they could increase the company’s share count; the cash component would also create an obligation if the relevant conditions are met. The practical test for the appointment will be whether Biotron can turn Gilbert’s stated priorities into a clearly funded sequence of SedRx and antiviral milestones.